Ngā hua rapu kaituhi

1

Towards a Unified Model of RAF Inhibitor Resistance mā Solit, David B., Rosen, Neal

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
2

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting mā Yaeger, Rona, Solit, David B.

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
3

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response mā Pratilas, Christine A., Solit, David B.

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
4

TARGETING ONCOGENIC BRAF IN HUMAN CANCER mā Pratilas, Christine, Xing, Feng, Solit, David

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
5

RAF/MEK dependence of KRAS mutant pancreatic ductal adenocarcinomas mā Hanrahan, Aphrothiti J., Solit, David B.

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
6

Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care mā Cheng, Michael L., Solit, David B.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
7

Precision Oncology: Three Small Steps Forward mā Wise, Hannah C., Solit, David B.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
8

Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells mā Redelman-Sidi, Gil, Iyer, Gopa, Solit, David, Glickman, Michael S.

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
9

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation mā Gounder, Mrinal M., Solit, David B., Tap, William D.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
10

The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E mā Veeriah, Selvaraju, Morris, Luc G., Solit, David, Chan, Timothy A.

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
11

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 mā Basso, Andrea D, Solit, David B, Munster, Pamela N, Rosen, Neal

I whakaputaina 2002

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
12

Clinical tumour sequencing for precision oncology: time for a universal strategy mā Cheng, Michael L., Berger, Michael F., Hyman, David M., Solit, David B.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
13

Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with (18)F-FDG PET mā Smith-Jones, Peter M., Solit, David, Afroze, Farzana, Rosen, Neal, Larson, Steven M.

I whakaputaina 2006

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
14

Proton MRS detects Metabolic Changes in Hormone Sensitive and Resistant Human Prostate Cancer Model CWR22 and CWR22r mā Le, H. Carl, Lupu, Mihaela, Kotedia, Khushali, Rosen, Neal, Solit, David, Koutcher, Jason A.

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
15

(V600E)BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway mā Pratilas, Christine A., Taylor, Barry S., Ye, Qing, Viale, Agnes, Sander, Chris, Solit, David B., Rosen, Neal

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
16

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells mā She, Qing-Bai, Solit, David B., Ye, Qing, O’Reilly, Kathryn E., Lobo, Jose, Rosen, Neal

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
17

PIK3CA mutation uncouples tumor growth and Cyclin D1 regulation from MEK/ERK and mutant KRAS signaling mā Halilovic, Ensar, She, Qing-Bai, Ye, Qing, Pagliarini, Raymond, Sellers, William R., Solit, David B., Rosen, Neal

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
18

Targeted next-generation sequencing of colorectal cancer identified metastatic specific genetic alterations mā Brannon, A Rose, Vakiani, Efsevia, Scott, Sasinya, Sylvester, Brooke, Kania, Krishan, Viale, Agnes, Solit, David, Berger, Michael

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
19

4E-BP1 Is A Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways That Integrates Their Function in Tumors mā She, Qing-Bai, Halilovic, Ensar, Ye, Qing, Zhen, Wei, Shirasawa, Senji, Sasazuki, Takehiko, Solit, David B., Rosen, Neal

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
20

Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma mā Gottesdiener, Lee S., O’Connor, Shannon, Busam, Klaus J., Won, Helen, Solit, David B., Hyman, David M., Shoushtari, Alexander N.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Solit, David

Towards a Unified Model of RAF Inhibitor Resistance mā Solit, David B., Rosen, Neal

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting mā Yaeger, Rona, Solit, David B.

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response mā Pratilas, Christine A., Solit, David B.

TARGETING ONCOGENIC BRAF IN HUMAN CANCER mā Pratilas, Christine, Xing, Feng, Solit, David

RAF/MEK dependence of KRAS mutant pancreatic ductal adenocarcinomas mā Hanrahan, Aphrothiti J., Solit, David B.

Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care mā Cheng, Michael L., Solit, David B.

Precision Oncology: Three Small Steps Forward mā Wise, Hannah C., Solit, David B.

Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells mā Redelman-Sidi, Gil, Iyer, Gopa, Solit, David, Glickman, Michael S.

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation mā Gounder, Mrinal M., Solit, David B., Tap, William D.

The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E mā Veeriah, Selvaraju, Morris, Luc G., Solit, David, Chan, Timothy A.

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 mā Basso, Andrea D, Solit, David B, Munster, Pamela N, Rosen, Neal

Clinical tumour sequencing for precision oncology: time for a universal strategy mā Cheng, Michael L., Berger, Michael F., Hyman, David M., Solit, David B.

Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with (18)F-FDG PET mā Smith-Jones, Peter M., Solit, David, Afroze, Farzana, Rosen, Neal, Larson, Steven M.

Proton MRS detects Metabolic Changes in Hormone Sensitive and Resistant Human Prostate Cancer Model CWR22 and CWR22r mā Le, H. Carl, Lupu, Mihaela, Kotedia, Khushali, Rosen, Neal, Solit, David, Koutcher, Jason A.

(V600E)BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway mā Pratilas, Christine A., Taylor, Barry S., Ye, Qing, Viale, Agnes, Sander, Chris, Solit, David B., Rosen, Neal

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells mā She, Qing-Bai, Solit, David B., Ye, Qing, O’Reilly, Kathryn E., Lobo, Jose, Rosen, Neal

PIK3CA mutation uncouples tumor growth and Cyclin D1 regulation from MEK/ERK and mutant KRAS signaling mā Halilovic, Ensar, She, Qing-Bai, Ye, Qing, Pagliarini, Raymond, Sellers, William R., Solit, David B., Rosen, Neal

Targeted next-generation sequencing of colorectal cancer identified metastatic specific genetic alterations mā Brannon, A Rose, Vakiani, Efsevia, Scott, Sasinya, Sylvester, Brooke, Kania, Krishan, Viale, Agnes, Solit, David, Berger, Michael

4E-BP1 Is A Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways That Integrates Their Function in Tumors mā She, Qing-Bai, Halilovic, Ensar, Ye, Qing, Zhen, Wei, Shirasawa, Senji, Sasazuki, Takehiko, Solit, David B., Rosen, Neal

Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma mā Gottesdiener, Lee S., O’Connor, Shannon, Busam, Klaus J., Won, Helen, Solit, David B., Hyman, David M., Shoushtari, Alexander N.

Ngā utauta rapu: